<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00736190</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-174-0123</org_study_id>
    <nct_id>NCT00736190</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Tenofovir Disoproxil Fumarate (DF) in Asian-American Adults With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Phase IV Study to Evaluate the Efficacy, Safety and Tolerability of Tenofovir DF in Asian-American Adults With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiviral activity and safety of tenofovir
      disoproxil fumarate (TDF) in Asian-American adults (self-reported Asian descent, living in
      the United States) with chronic hepatitis B infection. All participants will receive active
      treatment with TDF for 48 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy of TDF will be evaluated for reductions in serum HBV DNA, changes in liver enzymes,
      and the generation of antibody to the virus. Safety will be assessed by evaluating adverse
      events, laboratory abnormalities, and the development of drug resistance mutations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) &lt;400 Copies/mL (&lt;69 IU/mL)</measure>
    <time_frame>Week 48</time_frame>
    <description>Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Number of participants with normal ALT (at or below the upper limit of normal [ULN] for the central laboratory [34 U/L])at Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ALT Normalized (Baseline Values &gt; ULN [34 U/L] and &lt;= ULN at a Subsequent Visit) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA &lt;400 Copies/mL (&lt;69 IU/mL) and Normal ALT at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN [34 U/L]); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in FibroTest Value</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participant's age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion</measure>
    <time_frame>Week 48</time_frame>
    <description>HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBV DNA &lt; 169 Copies/mL (&lt;29 IU/mL) at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>Blood samples from study participants were collected for measuring HBV DNA via PCR method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of HBV DNA &lt;400 Copies/mL (&lt;69 IU/mL), Normal ALT, and HBeAg Loss</measure>
    <time_frame>Week 48</time_frame>
    <description>Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN [34 U/L]); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Composite Endpoint of HBV DNA &lt;400 Copies/mL (&lt;69 IU/mL), Normal ALT, and Seroconversion to Anti-HBe</measure>
    <time_frame>Week 48</time_frame>
    <description>Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Resistance Surveillance for Participants Without Virologic Breakthrough</measure>
    <time_frame>Week 48</time_frame>
    <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Resistance Surveillance for Participants With Virologic Breakthrough</measure>
    <time_frame>Week 48</time_frame>
    <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Resistance Surveillance for Participants Who Discontinued the Study Early</measure>
    <time_frame>Week 48</time_frame>
    <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300-mg tablet (marketed formulation) taken orally once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil fumarate</intervention_name>
    <description>300-mg tablet (marketed formulation) taken orally once daily</description>
    <arm_group_label>TDF</arm_group_label>
    <other_name>Viread</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Asian-American, defined as a person of self-reported Asian ancestry who is residing in
             the United States (US)

          -  18 through 75 years of age, inclusive

          -  Documented chronic HBV infection, defined as positive serum HBsAg =/&gt; 6 months

          -  HBV DNA =/&gt; 10,000 copies/mL (PCR method)

          -  ALT &gt; ULN and &lt;/= 10 Ã— ULN at screening or within the past 12 months prior to
             screening

          -  Willing and able to provide written informed consent

          -  Negative serum beta-human chorionic gonadotropin (HCG) pregnancy test (females of
             child-bearing potential)

          -  Estimated glomerular filtration rate (creatinine clearance) =/&gt; 60 mL/min/1.73m^2 by
             the Cockcroft-Gault equation

          -  Adequate hematologic function (absolute neutrophil count =/&gt; 1,500/mm^3; hemoglobin
             =/&gt; 10.0 g/dL)

          -  No prior TDF therapy; participants may have taken &lt; 12 weeks of oral anti-HBV therapy,
             with the last dose =/&gt; 16 weeks prior to screening; participants may have received
             prior interferon, but must have discontinued interferon therapy =/&gt; 6 months prior to
             screening

        Exclusion Criteria:

        Participants who meet any of the following exclusion criteria are not to be enrolled in
        this study.

          -  Pregnant women, women who are breast feeding or who believe they may wish to become
             pregnant during the course of the study.

          -  Males and females of reproductive potential who are not willing to use an effective
             method of contraception during the study. For males, condoms should be used and for
             females, a barrier contraception method should be used in combination with one other
             form of contraception.

          -  Decompensated liver disease defined as direct (conjugated) bilirubin &gt; 1.2 X ULN,
             prothrombin time (PT) &gt; 1.2 X ULN, platelets &lt; 150,000/mm3, or serum albumin &lt; 3.5
             g/dL

          -  Prior history of clinical hepatic decompensation (eg, ascites, jaundice,
             encephalopathy) or variceal hemorrhage

          -  Receipt of prior TDF treatment

          -  Receipt of =/&gt; 12 weeks of oral anti-HBV nucleoside/nucleotide therapy, or receipt of
             ANY oral anti-HBV treatment &lt; 16 weeks prior to screening

          -  Receipt of interferon (pegylated or not) therapy within 6 months of the Screening
             Visit

          -  alpha-fetoprotein &gt; 50 ng/mL

          -  Evidence of hepatocellular carcinoma (HCC)

          -  Co-infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
             hepatitis D virus (HDV)

          -  History of significant renal disease (eg, nephrotic syndrome, renal dysgenesis,
             polycystic kidney disease, congenital nephrosis, acute tubular necrosis, other renal
             disease)

          -  History of significant bone disease (eg, osteomalacia, chronic osteomyelitis,
             osteogenesis imperfecta, osteochrondroses, multiple bone fractures)

          -  Significant cardiovascular, pulmonary or neurological disease

          -  Evidence of a gastrointestinal malabsorption syndrome that may interfere with
             absorption of orally administered medications

          -  History of solid organ or bone marrow transplantation

          -  Ongoing therapy with any of the following: nephrotoxic agents, competitors of renal
             excretion (eg, probenecid), systemic chemotherapeutic agents, systemic
             corticosteroids, Interleukin-2 (IL-2) and other immunomodulating agents,
             investigational agents (except with the expressed approval of the Sponsor);
             administration of any of the above medications must be discontinued at least 30 days
             prior to the Baseline Visit and for the duration of the study period

          -  Known hypersensitivity to the study drugs, the metabolites, or formulation excipients

          -  Any other condition (including alcohol or substance abuse) or prior therapy that, in
             the opinion of the Investigator, would make the participant unsuitable for the study
             or unable to comply with dosing requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hacienda Heights</city>
        <state>California</state>
        <zip>91745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Laurel</city>
        <state>Maryland</state>
        <zip>20707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flushing</city>
        <state>New York</state>
        <zip>11355</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2008</study_first_posted>
  <results_first_submitted>July 7, 2011</results_first_submitted>
  <results_first_submitted_qc>July 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 3, 2011</results_first_posted>
  <last_update_submitted>November 30, 2011</last_update_submitted>
  <last_update_submitted_qc>November 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Tenofovir disoproxil fumarate</keyword>
  <keyword>Tenofovir DF</keyword>
  <keyword>Asian-American</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A: TDF</title>
          <description>Tenofovir disoproxil fumarate (TDF) 300 mg by mouth daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A: TDF</title>
          <description>Tenofovir disoproxil fumarate 300 mg by mouth daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="10.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian-Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Korean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Vietnamese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Cambodian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B virus (HBV) deoxyribonucleic acid (DNA)</title>
          <description>Plasma HBV DNA was analyzed using polymerase chain reaction (PCR) method.</description>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.484" spread="1.7678"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepatitis B e antigen (HBeAg)</title>
          <description>Blood samples were collected for HBV serology.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Antibody to HBeAg (Anti-HBe)</title>
          <description>Blood samples were collected for HBV serology.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive Hepatitis B surface antigen (HBsAg)</title>
          <description>Blood samples were collected for HBV serology.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase (ALT); upper limit of normal (ULN) = 34 U/L</title>
          <description>Blood samples were collected for serum chemistry.</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103.5" spread="149.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT (Multiples of ULN)</title>
          <description>Blood samples were collected for serum chemistry. Multiples are based on ULN of 34 U/L.</description>
          <units>multiples of ULN</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.628" spread="3.5698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT</title>
          <description>Blood samples were collected for serum chemistry. The ULN for ALT was 34 U/L.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HBV genotype</title>
          <description>Genotypic analysis was conducted at baseline for all participants.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Genotype B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Genotype C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) &lt;400 Copies/mL (&lt;69 IU/mL)</title>
        <description>Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method.</description>
        <time_frame>Week 48</time_frame>
        <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) &lt;400 Copies/mL (&lt;69 IU/mL)</title>
          <description>Blood samples were collected from study participants for measuring HBV DNA via polymerase chain reaction (PCR) method.</description>
          <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48</title>
        <description>Number of participants with normal ALT (at or below the upper limit of normal [ULN] for the central laboratory [34 U/L])at Week 48</description>
        <time_frame>Week 48</time_frame>
        <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alanine Aminotransferase (ALT) Normal at Week 48</title>
          <description>Number of participants with normal ALT (at or below the upper limit of normal [ULN] for the central laboratory [34 U/L])at Week 48</description>
          <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ALT Normalized (Baseline Values &gt; ULN [34 U/L] and &lt;= ULN at a Subsequent Visit) at Week 48</title>
        <description>A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L)</description>
        <time_frame>Week 48</time_frame>
        <population>The enrolled-and-treated analysis set included participants who were enrolled into the study, received at least one dose of study drug, and had baseline ALT &gt; ULN (34 U/L).</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ALT Normalized (Baseline Values &gt; ULN [34 U/L] and &lt;= ULN at a Subsequent Visit) at Week 48</title>
          <description>A normal value at Week 48 after having elevated ALT at baseline; normal ALT is defined as being at or below the ULN for the central laboratory (34 U/L)</description>
          <population>The enrolled-and-treated analysis set included participants who were enrolled into the study, received at least one dose of study drug, and had baseline ALT &gt; ULN (34 U/L).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA &lt;400 Copies/mL (&lt;69 IU/mL) and Normal ALT at Week 48</title>
        <description>Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN [34 U/L]); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
        <time_frame>Week 48</time_frame>
        <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Composite Endpoint of Hepatitis B Virus (HBV) DNA &lt;400 Copies/mL (&lt;69 IU/mL) and Normal ALT at Week 48</title>
          <description>Blood samples were collected for evaluating serum chemistry, including determination of ALT, and for measuring HBV DNA via PCR method. Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN [34 U/L]); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost hepatitis B e antigen (HBeAg) or developed antibody to hepatitis B e antigen (anti-HBe), only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
          <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in FibroTest Value</title>
        <description>The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participantâ€™s age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.</description>
        <time_frame>Baseline and Week 48</time_frame>
        <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FibroTest Value</title>
          <description>The FibroTest score is used to assess liver fibrosis and is calculated based on a formula including the participantâ€™s age and sex and 5 laboratory parameters: alpha 2 macroglobulin, haptoglobin, gamma-glutamyl transferase (GGT), bilirubin, and apolipoprotein A1. Scores can range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.</description>
          <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.1024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion</title>
        <description>HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48.</description>
        <time_frame>Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBeAg/Hepatitis B Surface Antigen (HBsAg) Loss and Seroconversion</title>
          <description>HBeAg/HBsAg loss is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- at Week 48. HBeAg/HBsAg serocoversion is defined for an individual participant as HBeAg+/HBsAg+ at baseline and HBeAg-/HBsAg- and anti-HBe+/antibody to hepatitis B surface antigen+ (anti-HBs+) at Week 48.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HBsAg+ at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg- at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg+ at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBsAg data missing at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg+ at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg- at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HBeAg loss by Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-HBe+ seroconversion by Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBV DNA &lt; 169 Copies/mL (&lt;29 IU/mL) at Week 48</title>
        <description>Blood samples from study participants were collected for measuring HBV DNA via PCR method.</description>
        <time_frame>Week 48</time_frame>
        <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBV DNA &lt; 169 Copies/mL (&lt;29 IU/mL) at Week 48</title>
          <description>Blood samples from study participants were collected for measuring HBV DNA via PCR method.</description>
          <population>The enrolled-and-treated analysis set included participants who were enrolled into the study and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of HBV DNA &lt;400 Copies/mL (&lt;69 IU/mL), Normal ALT, and HBeAg Loss</title>
        <description>Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN [34 U/L]); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
        <time_frame>Week 48</time_frame>
        <posting_date>01/2099</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Composite Endpoint of HBV DNA &lt;400 Copies/mL (&lt;69 IU/mL), Normal ALT, and Seroconversion to Anti-HBe</title>
        <description>Composite endpoints proposed in the protocol included the percentage of participants with HBV DNA &lt; 400 copies/mL (&lt;69 IU/mL) and normal ALT (ALT &lt;= ULN); and with HBV DNA &lt; 400 copies/mL, normal ALT, and HBeAg loss/seroconversion. Because so few participants lost HBeAg or seroconverted to anti-HBe, only the composite endpoint of HBV DNA &lt; 400 copies/mL and normal ALT was analyzed.</description>
        <time_frame>Week 48</time_frame>
        <posting_date>01/2099</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Resistance Surveillance for Participants Without Virologic Breakthrough</title>
        <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
        <time_frame>Week 48</time_frame>
        <population>10 participants received &gt;= 1 dose of study drug, remained viremic (HBV DNA &gt;= 400 copies/mL) after 48 weeks of TDF treatment, had serum sample for testing, and did not have virologic breakthrough (defined as HBV DNA &gt;= 400 copies/mL [confirmed] after having HBV DNA levels &lt; 400 copies/mL and/or 1-log10 increase [confirmed] in HBV DNA above nadir).</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Resistance Surveillance for Participants Without Virologic Breakthrough</title>
          <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
          <population>10 participants received &gt;= 1 dose of study drug, remained viremic (HBV DNA &gt;= 400 copies/mL) after 48 weeks of TDF treatment, had serum sample for testing, and did not have virologic breakthrough (defined as HBV DNA &gt;= 400 copies/mL [confirmed] after having HBV DNA levels &lt; 400 copies/mL and/or 1-log10 increase [confirmed] in HBV DNA above nadir).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No changes in HBV pol/RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes at polymorphic sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes at conserved sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Resistance Surveillance for Participants With Virologic Breakthrough</title>
        <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
        <time_frame>Week 48</time_frame>
        <population>2 participants received &gt;= 1 dose of study drug, remained viremic (HBV DNA &gt;= 400 copies/mL) after 48 weeks of TDF treatment, had serum sample for testing, and had virologic breakthrough (defined as HBV DNA &gt;= 400 copies/mL [confirmed] after having HBV DNA levels &lt; 400 copies/mL and/or 1-log10 increase [confirmed] in HBV DNA above nadir).</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Resistance Surveillance for Participants With Virologic Breakthrough</title>
          <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
          <population>2 participants received &gt;= 1 dose of study drug, remained viremic (HBV DNA &gt;= 400 copies/mL) after 48 weeks of TDF treatment, had serum sample for testing, and had virologic breakthrough (defined as HBV DNA &gt;= 400 copies/mL [confirmed] after having HBV DNA levels &lt; 400 copies/mL and/or 1-log10 increase [confirmed] in HBV DNA above nadir).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No changes in HBV pol/RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes at polymorphic sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes at conserved sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Resistance Surveillance for Participants Who Discontinued the Study Early</title>
        <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
        <time_frame>Week 48</time_frame>
        <population>2 participants received &gt;= 1 dose of study drug, discontinued TDF treatment after Week 24 with HBV DNA &gt;= 400 copies/mL, and had serum sample for testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir DF</title>
            <description>300-mg tablet (marketed formulation) taken orally once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Resistance Surveillance for Participants Who Discontinued the Study Early</title>
          <description>Serum was collected for HBV resistance surveillance, and sequence analysis of the HBV polymerase was assessed through di-deoxy sequencing of baseline and postbaseline samples.</description>
          <population>2 participants received &gt;= 1 dose of study drug, discontinued TDF treatment after Week 24 with HBV DNA &gt;= 400 copies/mL, and had serum sample for testing.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>No changes in HBV pol/RT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes at polymorphic sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes at conserved sites</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks + the follow-up off-study medication period (if applicable). Participants who permanently discontinued study drug were to be followed for 24 weeks off treatment or up to initiation of active treatment, whichever occurred first.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>A: TDF</title>
          <description>Tenofovir disoproxil fumarate 300 mg by mouth daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigators may discuss or publish results (without Gileadâ€™s confidential information) after all results have been publicly disclosed by/with consent of Gilead or study has been completed &gt;=2 years. Proposed publication/presentation and destination details must be submitted &gt;=30 days before submission. The investigator agrees to withhold publication or presentation for an additional 60 days in order to obtain patent protection if deemed necessary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eduardo Bruno Martins, MD, DPhil, Sr. Director, Medical Affairs - Hepatitis</name_or_title>
      <organization>Gilead Sciences, Inc.</organization>
      <phone>650-522-5792</phone>
      <email>eduardo.martins@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

